Clinical trials: Light-Chain Amyloidosis
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
Amyloidosis; Systemic
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
This is a single arm, open label study designed to evaluate the safety and efficacy of propylene glycol-free melphalan hydrochloride in patients with AL amyloidosis.
- Trial name
- NCT02994784
- Testing
- Propylene Glycol-Free Melphalan Hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Boston Medical Center
Amyloidosis, Immunoglobulin Light-chain
Cardiac Amyloidosis Registry Study
This registry is a observational, multi-center study designed to collect data and analyze it retrospectively on patients with cardiac amyloidosis who have been evaluated and treated at major amyloid centers across the US and…
- Trial name
- CARS (NCT05174338)
- Testing
- Registry
- Where
- 23 sites in United States, Canada
- Volunteers
- 5,000 people
- Sponsor
- Cedars-Sinai Medical Center
Light-chain Cardiac Amyloidosis
Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac Amyloidosis
The goal of this clinical trial is to evaluate whether selinexor combined with daratumumab and dexamethasone (XDd) can treat patients with advanced light-chain cardiac amyloidosis.
- Trial name
- NCT07743957
- Testing
- XDd
- Volunteers
- 63 people
- Sponsor
- Beijing Anzhen Hospital
Monoclonal Gammopathy of Renal Significance
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed monoclonal immunoglobulin deposition disease treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.
- Trial name
- NCT06418477
- Testing
- Dara-CyBorD
- Where
- 3 sites in China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Amyloid Cardiomyopathy, Congestive Heart Failure
Longitudinal Changes in Left and Right Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis
The purpose of this study to assess the longitudinal changes in left and right ventricular global strain after chemotherapeutic strategies in cardiac light chain amyloidosis.
- Conditions
- Amyloid Cardiomyopathy, Congestive Heart Failure, Chemotherapy Effect
- Trial name
- NCT05452850
- Testing
- Left and Right Ventricular Global Strain Imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul University - Cerrahpasa
Amyloidosis
Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis
High-dose melphalan (MEL) with autologous stem cell transplant (SCT) is an effective therapy for systemic AL amyloidosis (AL), but treatment-related mortality (TRM) has historically been high.
- Trial name
- NCT01527032
- Testing
- melphalan, thalidomide and dexamethasone
- Sponsor
- FDA Office of Orphan Products Development
Multiple Myeloma and Plasma Cell Neoplasm
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop plasma cells from growing.
- Trial name
- NCT00564889
- Testing
- cyclophosphamide, dexamethasone, lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Multiple Myeloma, AL Amyloidosis
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with…
- Conditions
- Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
- Trial name
- NCT05028374
- Testing
- A single "booster" dose of the Moderna mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Primary Systemic Amyloidosis (AL)
Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
AL amyloidosis is caused by a clonal plasma cell dyscrasia and characterized by progressive deposition of amyloid fibrils derived from monoclonal Ig light chains, leading to multisystem organ failure and death.
- Trial name
- NCT00344526
- Testing
- Melphalan, Dexamethasone, Autologous stem cell transplantation
- Where
- 8 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Limoges
Light Chain (AL) Amyloidosis, CCND1 Translocation
Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)
Venetoclax is considered as a promising agent for light-chain (AL) amyloidosis due to the high percentage of t(11;14). Several retrospective studies showed venetoclax-based therapy could induce rapid and profound hematologic…
- Conditions
- Light Chain (AL) Amyloidosis, CCND1 Translocation, Venetoclax
- Trial name
- NCT05996406
- Testing
- Venetoclax, Dexamethasone Oral
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Peking Union Medical College Hospital
Anemia, Leukemia
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00255749
- Testing
- epoetin alfa
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Recurrent Primary Amyloidosis
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
This randomized phase II trial studies how well lenalidomide, dexamethasone, and eotuzumab with or without cyclophosphamide work in treating patients with primary amyloidosis that has come back after a period of improvement.
- Trial name
- NCT03252600
- Testing
- Cyclophosphamide, Dexamethasone, Elotuzumab
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Amyloid Light-chain Amyloidosis
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
This research study is for people who have newly diagnosed with AL (light chain) amyloidosis and have not yet received any treatment for this condition.
- Trial name
- NCT07524634
- Testing
- BCMA bispecific
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004165
- Testing
- filgrastim, melphalan, peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Northwestern University
Systemic Light Chain Amyloidosis, Ocular Complications
The Impact of Systemic Light Chain Amyloidosis on Eyes
Study Purpose and Principle: Amyloidosis is a group of diseases characterized by the deposition of amyloid proteins in tissues and organs throughout the body, with common affected organs including kidneys, heart, nervous system…
- Trial name
- Amyloidosis (NCT06803082)
- Where
- China
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Smoldering Multiple Myeloma
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment.
- Trial name
- NCT06365060
- Where
- 13 sites in United States
- Volunteers
- 400 people
- Sponsor
- Tufts Medical Center
Multiple Myeloma and Plasma Cell Neoplasm
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00477971
- Testing
- filgrastim, dexamethasone, melphalan
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Mayo Clinic
Light Chain (AL) Amyloidosis
Daratumumab for Patients With Light Chain Amyloidosis
This is a prospective, single-center study exploratory clinical trial, aim to exploring the efficacy and safety of daratumumab in patients with AL amyloidosis, patients were divided into three groups: one group received long-term…
- Trial name
- NCT06376214
- Testing
- Dratumumab / Hyaluronidase Injection [Darzalex Faspro], Pomalidomide 4 MG, autologous stem cell transplantation (ASCT)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanjing University School of Medicine
Primary Light-Chain Amyloidosis
Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis
- Trial name
- NCT07039578
- Testing
- CM336 Injection(Low dose group), CM336 Injection(High dose group)
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Keymed Biosciences Co.Ltd